>Third party validation may not be as important as you would think it would be<
Agree and that’s why not having a partner ranks as low as #10 on my list of clinical/regulatory risks (#msg-15899257). I think most biotech investors place this much higher up.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”